News for Ocugen, Inc. (OCGN.MX)

Published at

Mar 18, 2025 3:00 PM

by gurufocus.com

positive

positive

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200--a Novel Fusion Protein for Diabetic Macular Edema

OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has

OCGN.MX OCGN

Read more →
Published at

Mar 5, 2025 4:59 PM

by seekingalpha.com

neutral

neutral

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ETCompany ParticipantsTiffany Hamilton - Head, Corporate...

OCGN.MX OCGN

Read more →
Published at

Mar 5, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt di

OCGN.MX OCGN

Read more →
Published at

Mar 5, 2025 1:43 PM

by gurufocus.com

positive

positive

Ocugen Inc (OCGN) Q4 Earnings: Revenue Surpasses Estimates at $0.76M, EPS Matches Expectations at -$0.05

Quarterly Revenue: $0.76 million, surpassing the estimated $0.30 million.Quarterly EPS: Reported a net loss of $0.05 per share, matching the estimated loss of

OCGN.MX OCGN

Read more →
Published at

Mar 3, 2025 2:30 PM

by financialpost.com

mixed

mixed

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) —

NYT DRVN OCGN.MX OCGN MRCY MEI GM

Read more →
Published at

Feb 27, 2025 3:00 PM

by gurufocus.com

positive

positive

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a pioneering biotechnology leader in gene therapies for blindnes

OCGN.MX OCGN

Read more →
Published at

Feb 24, 2025 11:16 PM

by financialpost.com

mixed

mixed

Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ:

Atkore Inc. (NYSE: ATKR):

NYT ATKR.MX ATKR OCGN.MX OCGN MEI CROX GM

Read more →
Published at

Feb 21, 2025 2:22 PM

by manilatimes.net

positive

positive

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

**media[546596]**

OCGN.MX OCGN

Read more →
Published at

Jan 27, 2025 1:00 PM

by gurufocus.com

positive

positive

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clini

OCGN.MX OCGN

Read more →
Published at

Jan 16, 2025 2:00 PM

by gurufocus.com

positive

positive

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200--a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (”Ocugen” or the ”Company”) ( OCGN), a biotechnology company focused on discovering, deve

OCGN.MX OCGN

Read more →
Published at

Jan 13, 2025 1:00 PM

by gurufocus.com

positive

positive

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 --A Novel Modifier Gene Therapy for Retinitis Pigmentosa

100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9

OCGN.MX OCGN

Read more →
Published at

Jan 13, 2025 12:44 PM

by manilatimes.net

positive

positive

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 -A Novel Modifier Gene Therapy for Retinitis Pigmentosa

**media[513301]**

OCGN.MX OCGN

Read more →
Published at

Dec 11, 2024 2:00 PM

by gurufocus.com

positive

positive

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a biotechnology company focused on discovering, developing, and

OCGN.MX OCGN

Read more →
Published at

Nov 27, 2024 2:00 PM

by gurufocus.com

positive

positive

Ocugen CEO to Present at NobleCon20 -- Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a biotechnology company focused on discovering, developing, and

OCGN.MX OCGN

Read more →
Published at

Nov 9, 2024 8:05 AM

by gurufocus.com

positive

positive

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Cash and Restricted Cash: $39 million as of September 30, 2024, compared to $39.5 million as of December 31, 2023.Total Operating Expenses: $14.4 million for t

OCGN.MX OCGN

Read more →
Published at

Nov 9, 2024 6:20 AM

by gurufocus.com

positive

positive

Q3 2024 Ocugen Inc Earnings Call Transcript

Nov 08, 2024 / 01:30PM GMTOperator Good morning and welcome to Ocugen's third quarter, 2024 financial results and business update. Please note that this call is

OCGN.MX OCGN

Read more →
Published at

Nov 8, 2024 4:18 PM

by seekingalpha.com

mixed

mixed

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Conference Call November 11, 2024 8:30 AM ETCompany ParticipantsTiffany Hamilton - Head of Corporate...

OCGN OCGN.MX

Read more →
Published at

Nov 8, 2024 1:07 PM

by manilatimes.net

positive

positive

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

**media[460166]**

OCGN.MX OCGN

Read more →
Published at

Oct 22, 2024 7:00 PM

by globenewswire.com

mixed

mixed

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The gene therapies market is experiencing significant growth, driven by advancements in research and technology. According to DelveInsight, the gene...

RV6.DE OCGN.MX OCGN JNJ DJNJ3.BA DJNJ2.BA CRL AGTC RARE.MX RARE

Read more →
Published at

Aug 6, 2024 1:46 PM

by rttnews.com

mixed

mixed

Pre-market Movers: LYT, LUMN, RXST, JMIA, HPAI…

UAE-based Lytus Technologies Holdings PTV. Ltd. (LYT) is up over 109 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

TDC SMFNF SMFG MED.MX MED LUMN.MX LUMN GOVXW GOVX 8316.T 0LEE.L 0LAF.L 0K05.L 0HVP.L ZI YOU PTX.DE PLTR OCGN.MX OCGN NKLA.MX NKLA MZHOF MFG LCID.MX JMIAN.MX JMIA INDO HUSA HSSHF DGHI.V CHGG CELH 8NI.DE 8411.T 0A7R.L 0A7K.L 0A4Z.L 0A44.L 0A3R.L

Read more →